Pharmaceuticals & Healthcare Industrial & Manufacturing

DPR & CMA Data on Disprin

Project Overview

Disprin is a popular over-the-counter analgesic and antipyretic medication primarily used to relieve pain and reduce fever. The active ingredient in Disprin is acetylsalicylic acid, commonly known as aspirin, which is known for its effectiveness in alleviating various types of pain, including headaches, muscle aches, and menstrual cramps. Disprin works by inhibiting the production of certain natural substances in the body that cause inflammation. This makes it a go-to choice for individuals seeking quick relief from discomfort. In addition to its pain-relieving properties, Disprin is also utilized for its antithrombotic effects, which can reduce the risk of heart attacks and strokes in certain populations. The brand has established a strong presence in various markets, leveraging its reputation and trust built over decades. Disprin's formulation also includes effervescent properties that enhance its solubility and speed of action, making it particularly popular among consumers who value prompt relief. The versatility of Disprin, combined with rising health awareness and the continuous increase in self-medication trends, contributes to its growing market demand. Furthermore, it remains competitive in the pharmaceutical space due to ongoing research, marketing initiatives, and consumer loyalty. The combination of affordability and effectiveness positions Disprin favorably in a crowded market of pharmaceuticals, allowing it to maintain a significant share among analgesics.

Market Potential

  • Increasing prevalence of pain-related disorders.
  • Growing consumer inclination towards self-medication.
  • Continued expansion into new geographic markets.
  • Rising awareness of chronic conditions and preventive treatments.

SWOT Analysis

Strengths

  • Established brand recognition and loyalty.
  • Proven efficacy and safety profile.
  • Wide distribution network.

Weaknesses

  • Potential gastrointestinal side effects.
  • Sensitivity among certain demographic groups (e.g. children).
  • Market saturation in some regions.

Opportunities

  • Expanding product lines with value-added formulations.
  • Leveraging digital marketing and e-commerce.
  • Growing demand for herbal and alternative therapies.

Threats

  • Intense competition from generic and alternative pain relief products.
  • Regulatory changes affecting pharmaceutical advertising.
  • Market entry of new innovative products.

Raw Materials Required

  • Acetylsalicylic acid
  • Citric acid
  • Sodium bicarbonate
  • Flavoring agents
  • Binding agents

Investment Profiles & Financial Analysis

This project has 4 investment scales. Select a profile to view its figures.

Micro

Capacity: 10 kg/month
Plant Capacity
10 kg/month
Machinery Cost
₹270,000 – ₹330,000
approx. range
Total Investment
₹446,000 – ₹545,000
approx. range
Working Capital (3M)
₹135,000 – ₹165,000
approx. range
Rate of Return
12.00%
Break-Even Point
65.00%
Break-even time: approx. 9 years
Projection quality
Strong projection
Market Demand
Rising
Increasing health consciousness and preference for reliable over-the-counter medications boost demand for products like Disprin.
Risk Level
Medium
Competition from established brands and regulatory compliance may pose challenges, impacting overall investment risk.
Skill Required
Intermediate
Producing pharmaceutical products requires understanding of formulation and quality standards, necessitating some level of expertise.
Notes:

Feasible for niche markets; potential for local demand.

Small

Capacity: 100 kg/month
Plant Capacity
100 kg/month
Machinery Cost
₹1,350,000 – ₹1,650,000
approx. range
Total Investment
₹1,985,000 – ₹2,426,000
approx. range
Working Capital (3M)
₹540,000 – ₹660,000
approx. range
Rate of Return
18.00%
Break-Even Point
50.00%
Break-even time: approx. 6 years
Projection quality
Strong projection
Market Demand
Rising
Increasing health awareness and preference for over-the-counter pain relief medications contribute to rising demand.
Risk Level
Medium
Moderate competition in the pharmaceutical sector and regulatory challenges present some investment risks.
Skill Required
Intermediate
Manufacturing disprin requires knowledge of pharmaceutical processes and compliance with health regulations.
Notes:

Good scalability; suitable for regional markets.

Medium

Capacity: 500 kg/month
Plant Capacity
500 kg/month
Machinery Cost
₹5,400,000 – ₹6,600,000
approx. range
Total Investment
₹8,316,000 – ₹10,164,000
approx. range
Working Capital (3M)
₹2,160,000 – ₹2,640,000
approx. range
Rate of Return
20.00%
Break-Even Point
55.00%
Break-even time: approx. 5 years
Projection quality
Strong projection
Market Demand
Rising
The increasing awareness of health and wellness is driving demand for pharmaceuticals and Ayurvedic medicines.
Risk Level
Medium
Competition in the pharmaceutical sector is significant, coupled with regulatory challenges that can impact operational stability.
Skill Required
Intermediate
Knowledge of pharmaceutical manufacturing and regulatory compliance is essential for successful operation and quality assurance.
Notes:

Promising growth; can target national distribution.

Large

Capacity: 2000 kg/month
Plant Capacity
2000 kg/month
Machinery Cost
₹22,500,000 – ₹27,500,000
approx. range
Total Investment
₹34,650,000 – ₹42,350,000
approx. range
Working Capital (3M)
₹9,000,000 – ₹11,000,000
approx. range
Rate of Return
25.00%
Break-Even Point
70.00%
Break-even time: approx. 4 years
Projection quality
Strong projection
Market Demand
Rising
The increasing awareness of health and wellness drives demand for pharmaceutical and Ayurvedic solutions.
Risk Level
Medium
Moderate competition in the pharmaceutical sector could impact market penetration and profitability.
Skill Required
Intermediate
Understanding formulation, regulatory compliance, and production processes require specialized knowledge.
Notes:

Highly scalable; potential to reach international markets.

Frequently Asked Questions

What is this project about?

Disprin is a popular over-the-counter analgesic and antipyretic medication primarily used to relieve pain and reduce fever. The active ingredient in Disprin is acetylsalicylic acid, commonly known as aspirin, which is known for its effectiveness in alleviating various types of pain, including headaches, muscle aches, and menstrual cramps. Disprin works by inhibiting the production of certain natural substances in the body that cause inflammation. This makes it a go-to choice for individuals seeking quick relief from discomfort. In addition to its pain-relieving properties, Disprin is also utilized for its antithrombotic effects, which can reduce the risk of heart attacks and strokes in certain populations. The brand has established a strong presence in various markets, leveraging its reputation and trust built over decades. Disprin's formulation also includes effervescent properties that enhance its solubility and speed of action, making it particularly popular among consumers who value prompt relief. The versatility of Disprin, combined with rising health awareness and the continuous increase in self-medication trends, contributes to its growing market demand. Furthermore, it remains competitive in the pharmaceutical space due to ongoing research, marketing initiatives, and consumer loyalty. The combination of affordability and effectiveness positions Disprin favorably in a crowded market of pharmaceuticals, allowing it to maintain a significant share among analgesics.

What is the market potential?

• Increasing prevalence of pain-related disorders.
• Growing consumer inclination towards self-medication.
• Continued expansion into new geographic markets.
• Rising awareness of chronic conditions and preventive treatments.

How much investment is required?

Total capital investment ranges from ₹495,000 to ₹38,500,000 depending on the scale of operation. This covers plant and machinery, civil work, pre-operative expenses, and working capital. Larger scales require proportionally higher investment but typically offer better returns.

When does this project break even?

At the larger investment scale, the expected break-even is approximately approx. 4 years at approximately 70.00% capacity utilisation. Smaller setups may reach break-even sooner due to lower fixed costs relative to the capacity.

What raw materials are required?

• Acetylsalicylic acid
• Citric acid
• Sodium bicarbonate
• Flavoring agents
• Binding agents

What are the key strengths of this project?

• Established brand recognition and loyalty.
• Proven efficacy and safety profile.
• Wide distribution network.

Related topics

Pain Relief Medicine